Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
As caveolin-1 and cavin family proteins are required for caveolae formation and function, the reported tumor suppression function of caveolin-1 and SRBC may be due to the deregulation of caveolae and its down-stream signaling.
|
21913217 |
2012 |
Neoplasms
|
0.080 |
AlteredExpression
|
group |
BEFREE |
Gene expression profiling identified PRKCDBP in the 11p15 region to be significantly downregulated in both BCBM and primary BC with brain relapse compared to primary tumors without relapse or bone metastasis (fdr<0.05). qRT-PCR confirmed these results and methylation was shown to be a common way to silence this gene.
|
23118876 |
2012 |
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
Selection in G418-containing medium produced CTLLR8 transfectant clones that: (1) expressed chimeric Fc(epsilon) receptor as determined by flow cytometry; (2) bound human IgE antibodies with high affinity as determined by Scatchard analysis; (3) specifically rosetted IgE-coated SRBC; (4) lysed target cells in IgE-mediated ADCC and reverse ADCC assays; and (5) retarded tumor growth in a Winn assay.
|
8975874 |
1996 |
Neoplasms
|
0.080 |
PosttranslationalModification
|
group |
BEFREE |
Our findings suggest that hSRBC is a novel tumor suppressor whose epigenetic inactivation contributes to the malignant progression of gastric tumors, in part, through attenuated p53 response to stresses.
|
18059034 |
2008 |
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
Protein kinase C delta binding protein (PRKCDBP/Cavin3/hSRBC) is a putative tumor suppressor that is downregulated in many human cancers.
|
25052149 |
2014 |
Neoplasms
|
0.080 |
AlteredExpression
|
group |
BEFREE |
PRKCDBP was induced by TNFα, and its level correlated with tumor cell sensitivity to TNFα-induced apoptosis.
|
21980136 |
2011 |
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
PRKCDBP is a putative tumor suppressor located at 11p15.4, where frequent genomic loss has been observed in human cancers.
|
23020606 |
2012 |
Neoplasms
|
0.080 |
GeneticVariation
|
group |
BEFREE |
Recently, the human SRBC (hSRBC) gene, a candidate tumor suppressor gene (TSG), has been mapped to the chromosomal region 11p 15.5--p15.4 where frequent allele loss has been described in lung cancer.
|
15940253 |
2005 |
Carcinogenesis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
To explore the implication of human SRBC gene [serum deprivation response factor-related gene product that binds to the c-kinase (hSRBC)] abnormality in ovarian tumorigenesis.
|
20423276 |
2010 |
Carcinogenesis
|
0.030 |
AlteredExpression
|
phenotype |
BEFREE |
We investigated expression and function of PRKCDBP in colorectal cells and tissues to explore its candidacy as a suppressor in colorectal tumorigenesis.
|
21980136 |
2011 |
Carcinogenesis
|
0.030 |
AlteredExpression
|
phenotype |
BEFREE |
To explore the candidacy of hSRBC as a suppressor of gastric tumorigenesis, we analyzed the expression and mutation status of hSRBC in gastric tissues and cell lines. hSRBC transcript was expressed in all normal and benign tumor tissues examined, but undetectable or very low in 73% (11/15) cancer cell lines and 41% (46/111) primary tumors.
|
18059034 |
2008 |
Colorectal Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
PRKCDBP is a proapoptotic tumor suppressor which is commonly altered in colorectal cancer by promoter hypermethylation, and its gene transcription is directly activated by NF-κB in response to TNFα.
|
21980136 |
2011 |
Colorectal Carcinoma
|
0.020 |
PosttranslationalModification
|
disease |
BEFREE |
These results provide a basis for future clinical studies to validate SRBC hypermethylation as a predictive marker for oxaliplatin resistance in colorectal cancer.
|
24273214 |
2014 |
Malignant neoplasm of lung
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Inactivation of human SRBC, located within the 11p15.5-p15.4 tumor suppressor region, in breast and lung cancers.
|
11691816 |
2001 |
Malignant neoplasm of lung
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Normal hSRBC protein expression was detected in only 18% of primary NSCLCs (N=93) by immunostaining and a significant association between loss of protein expression and methylation was found. hSRBC re-expression was observed after treatment of lung cancer cells with the demethylating agent 5-aza-2'-deoxycytidine.
|
15940253 |
2005 |
Malignant neoplasm of colon and/or rectum
|
0.020 |
Biomarker
|
disease |
BEFREE |
PRKCDBP is a proapoptotic tumor suppressor which is commonly altered in colorectal cancer by promoter hypermethylation, and its gene transcription is directly activated by NF-κB in response to TNFα.
|
21980136 |
2011 |
Malignant neoplasm of colon and/or rectum
|
0.020 |
PosttranslationalModification
|
disease |
BEFREE |
These results provide a basis for future clinical studies to validate SRBC hypermethylation as a predictive marker for oxaliplatin resistance in colorectal cancer.
|
24273214 |
2014 |
Malignant neoplasm of breast
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Gene expression profiling identified PRKCDBP in the 11p15 region to be significantly downregulated in both BCBM and primary BC with brain relapse compared to primary tumors without relapse or bone metastasis (fdr<0.05). qRT-PCR confirmed these results and methylation was shown to be a common way to silence this gene.
|
23118876 |
2012 |
Malignant Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
To explore the candidacy of hSRBC as a suppressor of gastric tumorigenesis, we analyzed the expression and mutation status of hSRBC in gastric tissues and cell lines. hSRBC transcript was expressed in all normal and benign tumor tissues examined, but undetectable or very low in 73% (11/15) cancer cell lines and 41% (46/111) primary tumors.
|
18059034 |
2008 |
Malignant neoplasm of endometrium
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Genetic polymorphism of PRKCDBP is associated with an increased risk of endometrial cancer.
|
23020606 |
2012 |
Ulcerative Colitis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
To explore the potential of PRKCDBP as a diagnostic or prognostic marker for inflammatory bowel disease, the possible correlation between its expression status and TNF-α signaling was evaluated in ulcerative colitis (UC) patients, both pre- and post-infliximab (IFX) therapy.
|
25052149 |
2014 |
Depressive disorder
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Our aim was to study SDPR, PRKCDBP, CRY1 and CRY2 genetic variants in depressive disorders.
|
27721187 |
2017 |
Hepatitis C
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Cavin-1, cavin-2, and cavin-3 proteins and their gene expression were examined using immunohistochemistry (IHC), Western blotting, and laser capture microdissection (LCM)-polymerase chain reaction (PCR) during progression of cirrhosis caused by hepatitis C. According to the perfusion, fixation methods were designed to reevaluate the precise ultrastructural localizations and changes of cavin-1 and cavin-2 expression on liver sinusoidal endothelial cells (LSECs) facing the sinusoidal blood flow.
|
26086560 |
2015 |
Inflammatory Bowel Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
To explore the potential of PRKCDBP as a diagnostic or prognostic marker for inflammatory bowel disease, the possible correlation between its expression status and TNF-α signaling was evaluated in ulcerative colitis (UC) patients, both pre- and post-infliximab (IFX) therapy.
|
25052149 |
2014 |
Liver Cirrhosis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Cavin-1, cavin-2, and cavin-3 proteins and their gene expression were examined using immunohistochemistry (IHC), Western blotting, and laser capture microdissection (LCM)-polymerase chain reaction (PCR) during progression of cirrhosis caused by hepatitis C. According to the perfusion, fixation methods were designed to reevaluate the precise ultrastructural localizations and changes of cavin-1 and cavin-2 expression on liver sinusoidal endothelial cells (LSECs) facing the sinusoidal blood flow.
|
26086560 |
2015 |